

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

KINGDOM
KINGDOM HOLDINGS LIMITED
金達控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 528)

CLARIFICATION ANNOUNCEMENT

This announcement is made by Kingdom Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to clarify certain statements contained in an announcement (the “**Announcement**”) published by Creso Pharma Limited (“**Creso**”), a company listed on the Australian Stock Exchange (ASX: CPH), on 20 November 2017.

The board (the “**Board**”) of directors (“**Directors**”) of the Company notes that in the Announcement regarding the entering into a strategic partnership and commercial distribution agreement by Creso with Zhejiang Kingdom Creative Co., Ltd (浙江金達創業股份有限公司) (“**Kingdom Creative**”) for the distribution of certain healthcare therapeutics and products across the People’s Republic of China (“the “**PRC**”), it was incorrectly stated that Kingdom Creative was a subsidiary of the Company.

The Board wishes to clarify that, as at the date of this announcement, to the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, Kingdom Creative is a joint stock company established in the PRC with limited liability which is owned as to 69.30% by Mr. Ren Weiming, the chairman of the Company and an executive Director and has a diversified investment portfolio including retail business, banking, finance leasing and biotechnology companies. Accordingly, Kingdom Creative is not a subsidiary of the Company and does not form part of the Group. The Board further confirms that the Group’s principal business is the manufacturing and sales of linen yarn and, as at the date of this announcement, the Group has no intention to enter into any agreement with any third party for distribution of healthcare therapeutics and products across the PRC.

As the Announcement has not been verified or authorised by the Company, shareholders and potential investors of the Company are advised to rely on information released by the Company and exercise caution when dealing in the shares of the Company.

By Order of the Board of
Kingdom Holdings Limited
Ren Weiming
Chairman

Zhejiang, the PRC,
23 November 2017

As at the date of this announcement, the executive Directors are Mr. Ren Weiming, Mr. Shen Yueming, Mr. Zhang Hongwen and Ms. Shen Hong; the non-executive Director is Mr. Ngan Kam Wai Albert; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Lo Kwong Shun Wilson and Mr. Yan Jianmiao.